SLC5A2 and diabetic ketoacidosis: The U.S. FDA publicly recognized the potential of euglycemic diabetic ketoacidosis (euDKA) with SGLT2 inhibitors in a Drug Safety Communication published in 2015 based on postmarketing surveillance data obtained through the FDA Adverse Event Reporting System (FAERS) database [35].